{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018426","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.962093+00:00","generated_at":"2026-06-02T06:37:49.117824+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lantern Pharma Q1 2024 net loss $5.4M, cash $38.4M; clinical trials advance","bullets":["Net loss $5.4M ($0.51/share) vs $3.9M ($0.36/share) in Q1 2023; R&D expense $4.3M vs $2.6M.","Cash, cash equivalents & marketable securities $38.4M at Mar 31, 2024, down from $41.3M at Dec 31, 2023.","Phase 1 trials for LP-184 and LP-284 continue with no dose-limiting toxicities; LP-184 enrollment to complete summer 2024.","Regulatory allowance granted to begin Phase 2 Harmonic trial in Japan and Taiwan for LP-300 in never-smoker NSCLC.","ADC program advanced: novel cryptophycin-based ADC shows picomolar potency and 80% cancer cell kill rate in preclinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018426","json":"https://secwatch.observer/filing/0001493152-24-018426.json","markdown":"https://secwatch.observer/filing/0001493152-24-018426.md","text":"https://secwatch.observer/filing/0001493152-24-018426.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:37:49.117824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38d97d338a28e35a54984ef8c371b58d0547c2ec","claim":"Lantern Pharma Inc. reported financial results for the first quarter 2024.","evidence_excerpt":"On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}